Turn Therapeutics enters global supply and development pact with Medline for PermaFusion platform

Turn Therapeutics Inc.

Turn grants Medline exclusive worldwide license to use Turn's 510(k) clearance for wound-care field-of-use.
Medline to lead global commercialization across 100+ countries; Turn provides formulation expertise, IP, and clinical development.
Initial term of three years with automatic one-year renewals; exclusivity subject to undisclosed volume thresholds.
Parties to collaborate on line extensions (foams, films, hydrogels, ointments, dressings) incorporating PermaFusion technology.
Public announcement required within 72 hours of October 23, 2025 effective date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.